Author

Q. J. Liu

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Assay:proteomics· 2 Approach:statistical model· 1

Frequent Co-Authors

K. S. Carmon· 3 shared S. Park· 2 shared W. A. Yu· 2 shared J. Cui· 1 shared J. H. Rowe· 1 shared J. Jacob· 1 shared J. Tu· 1 shared L. E. Francisco· 1 shared

Activity by Year

2019-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 23 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

K. S. Carmon

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

An antibody-drug conjugate targeting GPR56 demonstrates efficacy in preclinical models of colorectal cancer

J. Jacob, L. E. Francisco, T. Chatterjee, Z. Liang, S. Subramanian, Q. J. Liu, J. H. Rowe, K. S. Carmon

This study develops an antibody-drug conjugate targeting GPR56 and shows it is effective against colorectal cancer models.

bioRxiv · Aug 11, 2022Cancer Biology

Drug Conjugates of Antagonistic RSPO4 Mutant For Simultaneous Targeting of LGR4/5/6 for Cancer Treatment

J. Cui, S. Park, W. A. Yu, K. S. Carmon, Q. J. Liu

This paper develops RSPO4 mutant-based peptibody drug conjugates that target LGR4/5/6, showing potent cytotoxic effects and tumor suppression in vitro and in vivo.

bioRxiv · Feb 5, 2021 · PreprintPharmacology & Toxicology

The most common RNF43 mutant G659Vfs41 is fully functional in inhibiting Wnt signaling and unlikely to play a role in tumorigenesis

J. Tu, S. Park, W. A. Yu, S. Zhang, L. Wu, K. S. Carmon, Q. J. Liu

The paper shows that the RNF43-G659Vfs41 mutation is functional and not a driver mutation in tumorigenesis, but may be a passenger mutation in MLH1-downregulated tumors.

bioRxiv · Jul 22, 2019Cancer Biology